Literature DB >> 6049399

The adenylate kinase of human plasma, erythrocytes and platelets in relation to the degradation of adenosine diphosphate in plasma.

R J Haslam, D C Mills.   

Abstract

1. Adenylate kinase (EC 2.7.4.3) has been shown to be present in human plasma obtained by conventional means and the adenylate-kinase activities of plasma and of lysed and intact human platelets and erythrocytes have been measured at 37 degrees by sensitive spectrophotometric methods. 2. The activities found in plasma ranged from 2.7 to 22.9mumoles of ADP formed/min./l. and in lysed platelets and lysed erythrocytes mean values of 0.79 and 12.0mumoles of ADP formed/min./10(9) cells respectively were found. Intact platelets and erythrocytes showed little or no activity. 3. The apparent K(m) of plasma adenylate kinase for ADP was found to be 1.4-1.6mm. 4. The adenylate-kinase activity of plasma was correlated with the free haemoglobin present and the larger part of the activity could be accounted for by haemolysis occurring either during the withdrawal of the blood or in vivo. 5. Aggregation of platelets by ADP, collagen fibres or thrombin released up to 16% of the platelet adenylate kinase into the suspending medium. 6. Measurement of the rate of breakdown of 1.6mum-ADP in plasma gave values of about 0.1mmu-mole/min./ml. This was not increased by addition of sufficient erythrocyte lysate to increase the activity of plasma adenylate kinase five to ten times. 7. It was concluded that the activity of adenylate kinase found in plasma, even after aggregation of the platelets, is insufficient to account for the rate of breakdown of low concentrations of ADP usually observed, and that another enzyme is responsible for this process.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6049399      PMCID: PMC1270482          DOI: 10.1042/bj1030773

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  17 in total

1.  STOICHIOMETRY AND LOCALIZATION OF ADENOSINE TRIPHOSPHATE-DEPENDENT SODIUM AND POTASSIUM TRANSPORT IN THE ERYTHROCYTE.

Authors:  A K SEN; R L POST
Journal:  J Biol Chem       Date:  1964-01       Impact factor: 5.157

2.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

3.  Enzymes of the red blood cell membrane: adenylate kinase activity.

Authors:  P CERLETTI; G DE RITIS
Journal:  Clin Chim Acta       Date:  1962-05       Impact factor: 3.786

4.  Kinetic studies on rabbitmuscle myokinase.

Authors:  O H CALLAGHAN; G WEBER
Journal:  Biochem J       Date:  1959-11       Impact factor: 3.857

5.  Adenylate kinase of mammalian erythrocytes.

Authors:  P CERLETTI; E BUCCI
Journal:  Biochim Biophys Acta       Date:  1960-02-12

6.  The metabolism of the erythrocyte. XV. Adenylate kinase of the erythrocyte.

Authors:  S KASHKET; O F DENSTEDT
Journal:  Can J Biochem Physiol       Date:  1958-10

7.  Further modification of the benzidine method for measurement of hemoglobin in plasma; definitionn of a new range of normal values.

Authors:  G E HANKS; M CASSELL; R N RAY; H CHAPLIN
Journal:  J Lab Clin Med       Date:  1960-09

8.  Kinetic studies on the breakdown of adenosine diphosphate in human plasma.

Authors:  H Holmsen; H Stormorken; T M Goote
Journal:  Scand J Clin Lab Invest       Date:  1965       Impact factor: 1.713

9.  Changes in nucleotides following the addition of adenosine diphosphate to platelet suspensions.

Authors:  J R Turtle; B G Firkin
Journal:  Australas Ann Med       Date:  1965-11

10.  Detection and determination of adenosine diphosphate and related substances in plasma.

Authors:  D M Ireland; D C Mills
Journal:  Biochem J       Date:  1966-05       Impact factor: 3.857

View more
  15 in total

1.  Hereditary hemolytic anemia with human erythrocyte pyrimidine 5'-nucleotidase deficiency.

Authors:  W N Valentine; K Fink; D E Paglia; S R Harris; W S Adams
Journal:  J Clin Invest       Date:  1974-10       Impact factor: 14.808

Review 2.  Platelet disorders: a review of disturbances in adhesion, aggregation, and release reaction.

Authors:  M A Sahud
Journal:  Calif Med       Date:  1972-01

3.  Evidence against a common subunit in adenylate kinase and pyruvate kinase.

Authors:  D J Brock
Journal:  Humangenetik       Date:  1970-08-17

4.  Adenylate kinase isoenzyme patterns in tissues of people of different phenotype.

Authors:  D J Brock
Journal:  Biochem Genet       Date:  1970-10       Impact factor: 1.890

5.  Submitochondrial localization and asymmetric disposition of two peripheral cyclic nucleotide phosphodiesterases.

Authors:  B Cercek; M D Houslay
Journal:  Biochem J       Date:  1982-10-01       Impact factor: 3.857

6.  Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities.

Authors:  Gennady G Yegutkin; Bé Wieringa; Simon C Robson; Sirpa Jalkanen
Journal:  FASEB J       Date:  2012-05-25       Impact factor: 5.191

7.  Studies on the kinetic properties and subcellular localization of adenine nucleotide phosphatases in peripheral blood lymphocytes from control subjects and patients with common variable primary hypogammaglobulinaemia.

Authors:  G P Smith; T Shah; A D Webster; T J Peters
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

8.  Lead poisoning: association with hemolytic anemia, basophilic stippling, erythrocyte pyrimidine 5'-nucleotidase deficiency, and intraerythrocytic accumulation of pyrimidines.

Authors:  W N Valentine; D E Paglia; K Fink; G Madokoro
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

9.  Uptake, metabolism and release of (3H)-adrenaline by human platelets.

Authors:  G V Born; J B Smith
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

10.  The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation.

Authors:  D C Mills; I A Robb; G C Roberts
Journal:  J Physiol       Date:  1968-04       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.